A Phase 4 interventional study of Nifedipine (Adalat, BAYA1040) and Amlodipine (Norvasc) in Hypertension, sponsored by Bayer. Completed at 4 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-01-26.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.
Among the 29 studies testing nifedipine in Hypertension, this one is the 2nd largest by enrollment, is the only one that started in 2004, is one of 12 in phase 4, and was the 14th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18+ · Women only
Nebraska Methodist Health System · Sites in United States
Ages 19+ · Women only
By country, each count listing its studies:
Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 9 · Phase 4 12
First in 2003; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 514 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 72 across the 29 interventional studies. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 29 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
33 studies in Hypertension by Bayer: none open now, none under way, none of them phase 3. Of 31 finished, 4 (13%) have results posted.
Among the 33 studies in Hypertension by Bayer, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 4, and was the 25th registered.
Bayer’s Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing nifedipine in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate incremental cost effectiveness of Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of essential hypertensive patients.
To investigate incremental cost effectiveness, primary variables are mean treatment cost and achievement rate to target blood pressure level at the end of double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry (Visit 1) is:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalat CR 20-40mg od + Diovan 40-80mg od
Drug: Nifedipine (Adalat, BAYA1040) · Drug: Diovan
Norvasc 2.5-5mg od + Diovan 40-80mg od
Drug: Amlodipine (Norvasc) · Drug: Diovan
Mean treatment cost* for 16-week of double-blind treatment period
\* Including treatment cost for the drug related AEs. The sponsor will calculate the cost based on the tariff of health insurance scores.
Time frame: 16 weeks
Proportion of participants** achieving target blood pressure at the end of double-blind treatment period
\*\*For subjects aged under 60 years: SBP\<130mmHg and DBP\<85mmHg, for subjects aged 60 years or over: SBP\<140mmHg and DBP\<90mmHg (SBP Systolic blood pressure, DBP Diastolic blood pressure)
Time frame: at week 16
Treatment cost per subject to achieve the target blood pressure (Total costs for the double-blind treatment period / Number of patients who achieve the target blood pressure at the end of double-blind treatment period)
Time frame: 16 weeks
The change in blood pressure (SBP and DBP) from the baseline (end of pretreatment period) .
Time frame: baseline to week 16
Proportion of participants for each age group to target blood pressure level
Time frame: at week 16
Incidence of treatment-emergent drug-related adverse events
Time frame: 16 weeks
Safety variables will be summarized using descriptive statistics based on adverse events collections
Time frame: 16 weeks
The record gives a start of Mar 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nifedipine